Lineage: AFFO Beat and Raised Guidance vs. High Leverage Reality Check

What happened

Lineage's Q2 2026 results beat expectations with AFFO per share at $0.76 (down 6.2% YoY) and management raised full-year guidance to $2.80–$3.05, suggesting operational resilience despite macro headwinds. The Seeking Alpha article highlights the company's technological and operational advantages, but notes higher leverage (net debt/EBITDA at 6.0x) and industry risks. This contrasts with our prior DeepValue report's more dire metrics: net debt/EBITDA of 12.26x and interest coverage of 0.90x, based on 2024–H1 2025 data, indicating either significant deleveraging or a discrepancy in metric definitions between sources. While the raised guidance implies a forward AFFO multiple of ~13-14x, which is reasonable for a REIT, the controlled company governance and still-subdued interest coverage (if not markedly improved) keep risk elevated. The market appears to be pricing in a steady recovery, but we remain cautious given the lack of clarity on balance sheet improvements and the reliance on adjusted metrics.

Implication

The Q2 beat and raised guidance are positive signals that the cold-chain platform is generating cash flow despite challenges, but the AFFO decline year-over-year shows the recovery is not yet robust. The discrepancy in net debt/EBITDA (6.0x per article vs. 12.26x per our prior model) must be resolved; if the lower figure is accurate, then deleveraging has been substantial and could support a shift to HOLD, but if the higher figure persists, the balance sheet remains fragile. The forward AFFO multiple of ~13-14x is not demanding, but it relies on hitting the midpoint of guidance and does not fully price in the risks from high fixed costs, interest burden, and governance overhang. We would need to see sustained interest coverage above 2x and further evidence of occupancy/storage rate strength before turning constructive, as our watch list specifies. For now, we maintain a cautious stance: the recovery may be delayed but not broken, yet the risk/reward is not compelling enough for a Buy given the unresolved balance sheet uncertainty.

Thesis delta

Our prior SELL was based on extreme leverage (12.26x Net Debt/EBITDA), interest coverage below 1x, and a DCF valuation far above intrinsic value. The new article's report of 6.0x net debt/EBITDA and raised AFFO guidance suggests the financial profile may have improved meaningfully, potentially warranting a shift to HOLD if confirmed. However, until we can verify the lower leverage from primary sources and see sustained interest coverage improvement, we retain a cautious outlook and do not yet endorse a Buy.